MELISSA MAYHAN: Open Payments
NPI 1487246278 · LITTLE ROCK, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,675 in 141 payments from 18 companies in 2025. Trend: 2023 $1,908 · 2024 $2,121 · 2025 $2,675
Food & beverage: $2,635Consulting: $40
| Company | Payments | Amount |
|---|---|---|
| ARS Pharmaceuticals Operations, Inc. | 21 | $325 |
| AstraZeneca Pharmaceuticals LP | 15 | $318 |
| Novartis Pharmaceuticals Corporation | 14 | $302 |
| CSL Behring | 14 | $282 |
| GlaxoSmithKline, LLC. | 18 | $230 |
| Regeneron Healthcare Solutions, Inc. | 8 | $209 |
| GENZYME CORPORATION | 9 | $196 |
| Genentech USA, Inc. | 10 | $185 |
| LEO Pharma Inc. | 10 | $166 |
| Grifols USA, LLC | 4 | $88 |
Products named: NEFFY, DUPIXENT, Hizentra, Rhapsido, AIRSUPRA, Xolair, NUCALA, TEZSPIRE.
Industry payments across AR — which companies pay providers there.
